Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934526 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
A Phase 3 study, sponsored by GB002.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT05934526: Completed Phase 3 study, sponsored by GB002.
NCT05934526 is a Phase 3 study that has completed, run by GB002. The registered enrollment target is 390 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05934526, a Phase 3 study, has completed, sponsored by GB002.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Interventions
- DRUG Placebo
- DEVICE Generic Dry Powder Inhaler
- DRUG Seralutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 3 |
What the finished NCT05934526 record still lists
NCT05934526 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05934526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05934526 about?
NCT05934526 is a clinical study titled "Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)". The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
What is the current status of trial NCT05934526?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2023-12-28. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT05934526?
The interventions under investigation include: Placebo (DRUG), Generic Dry Powder Inhaler (DEVICE), Seralutinib (DRUG).
Who is sponsoring clinical trial NCT05934526?
This trial is sponsored by GB002, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05934526's enrollment target sits among peer trials
390 968th of 2000 higher than 1,029 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI